Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects. (BIOMOHS)
A Multicenter, Prospective, Randomized Controlled Clinical Trial Assessing the Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects.
A multicenter, prospective, randomized controlled clinical trial assessing the efficacy of a novel cellular, acellular, matrix-like product (CAMP) plus standard of care versus standard of care alone in the management of post-mohs micrographic surgery defects.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This study will utilize a Prospective, Multicenter, Randomized Controlled Clinical Trial design.
Subjects will be adult patients undergoing Mohs micrographic surgery with resulting post-excisional defects suitable for healing by secondary intention or management with a topical matrix-like product.
Subjects will be randomized to receive:
- CAMP plus Standard of Care (SOC), or
- Control Dressing plus SOC. Randomization will occur after confirmation of final Mohs stage and measurement of the post-excisional defect.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Bennett Sarver
- Telefonnummer: 1-833-865-6300
- E-mail: info@serenagroups.com
Studiesteder
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74132
- Rekruttering
- Southside Dermatology Mohs and Skin Surgery
-
Kontakt:
- Ana Montalva
- Telefonnummer: (918) 760-0700
- E-mail: amontalva@dermatologyok.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
The potential subject must be at least 18 years of age or older.
-
The potential subject must have undergone Mohs micrographic surgery for a cutaneous malignancy (e.g., basal cell carcinoma, or squamous cell carcinoma).
-
The potential subject must have a post-Mohs surgical defect that is suitable for treatment with a CAMP product or healing by secondary intention.
-
The surgical site has received standard Mohs excision and hemostasis with no requirement for immediate flap or graft reconstruction as determined by the treating surgeon.
-
If the surgical defect is on the lower extremity, the limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
- Toe-Brachial Index (TBI) ≥ 0.6;
- Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
- Pulse Volume Recording (PVR): biphasic.
-
If the subject has multiple Mohs defects, they must be separated by at least 2 cm. The largest defect satisfying the inclusion and exclusion criteria will be designated as the target wound.
-
The potential subject must agree to attend the weekly study visits required by the protocol.
-
The potential subject must be willing and able to participate in the informed consent process.
Exclusion Criteria:
-
The potential subject is known to have a life expectancy of < 6 months.
-
The potential subject's target wound is not secondary to a Mohs excision.
-
The target wound is infected or there is cellulitis in the surrounding skin.
-
The target wound:
- Exposes tendon, bone, or joint space, and/or
- Requires immediate complex flap or graft reconstruction in the judgment of the surgeon.
-
The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
-
The potential subject has glycated hemoglobin (HbA1c) greater than 10% within 3 months of the initial screening visit.
-
The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Control Dressing + Standard of Care
Standard of care will be cleaning, debridement, ulcer moisture balance, control dressing and offloading. |
Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
|
Andet: CAMP + Standard of Care
Membrane Wrap-Lite is a human amniotic membrane tissue allograft derived from human placental tissue. |
Participants will receive weekly applications of Membrane Wrap-Lite and Standard of Care until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Wound Closure
Tidsramme: 1-6 Weeks
|
The percentage of target wounds achieving complete wound closure in 6 weeks. |
1-6 Weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Closure
Tidsramme: 1-6 Weeks
|
Time to closure for the target wound. |
1-6 Weeks
|
|
Percentage Area Reduction
Tidsramme: 1-6 weeks
|
Percentage wound area reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 weeks
|
|
Procedure-Related Adverse Events
Tidsramme: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Wound Volume Reduction
Tidsramme: 1-6 Weeks
|
Percentage wound volume reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 Weeks
|
|
Product or Procedure Adverse Events
Tidsramme: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Numeric Pain Scale
Tidsramme: 1-6 weeks
|
Change in pain at the target wound site assessed using a numeric pain scale. 0 being no pain and 10 being the worst pain imaginable. |
1-6 weeks
|
|
Economic Outcomes
Tidsramme: 1-6 Weeks
|
Health economic outcomes, including direct and indirect cost of care. |
1-6 Weeks
|
|
Quality of Life
Tidsramme: 1- 6 Weeks
|
Change in quality of life, using the Wound Quality of Life Questionnaire, with items scored 0-4, where higher scores indicate worse quality of life. |
1- 6 Weeks
|
|
Scare and Cosmetic Outcomes
Tidsramme: 12 Months
|
Scar and cosmetic outcomes at 12 months using the Patient and Observer Scar Assessment Scale (POSAS). 0 being normal and 10 being very different. |
12 Months
|
|
Time to Complete Granulation Tissue
Tidsramme: 1-6 Weeks
|
Time to complete granulation tissue confirmed by independent assessment. |
1-6 Weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Perfusion
Tidsramme: 1-6 Weeks
|
Changes in local perfusion at the surgical site over the 6-week treatment period, assessed via near-infrared spectroscopy. |
1-6 Weeks
|
|
Rate of Recurrence
Tidsramme: 12 Months
|
The rate of recurrence within 12 months of closure when applicable. |
12 Months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Thomas Serena, MD, Serena Group, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- To be determined
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .